Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for PROCEPT BioRobotics (PRCT) over the last 6 years, with Q3 2025 value amounting to $1.1 million.

  • PROCEPT BioRobotics' Cash from Financing Activities fell 3720.12% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.3 million, marking a year-over-year increase of 132245.85%. This contributed to the annual value of $180.1 million for FY2024, which is 734.83% up from last year.
  • As of Q3 2025, PROCEPT BioRobotics' Cash from Financing Activities stood at $1.1 million, which was down 3720.12% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, PROCEPT BioRobotics' Cash from Financing Activities ranged from a high of $174.1 million in Q3 2021 and a low of -$1.3 million during Q4 2022
  • Over the past 5 years, PROCEPT BioRobotics' median Cash from Financing Activities value was $2.4 million (recorded in 2023), while the average stood at $32.7 million.
  • As far as peak fluctuations go, PROCEPT BioRobotics' Cash from Financing Activities tumbled by 30465.84% in 2022, and later soared by 2076473.62% in 2023.
  • Over the past 5 years, PROCEPT BioRobotics' Cash from Financing Activities (Quarter) stood at $644000.0 in 2021, then crashed by 304.66% to -$1.3 million in 2022, then soared by 317.45% to $2.9 million in 2023, then soared by 5850.03% to $170.5 million in 2024, then plummeted by 99.37% to $1.1 million in 2025.
  • Its Cash from Financing Activities was $1.1 million in Q3 2025, compared to $4.4 million in Q2 2025 and $1.3 million in Q1 2025.